The home pregnancy test is one of the most quietly successful diagnostics ever made. Cheap, private, instant, and readable by anyone. Kalia Health has spent years chasing a stubborn question: if a strip can tell you a pregnancy has started, why can't one warn you when that pregnancy turns dangerous? The company is building Kal-PDx, a urine test meant to screen for preeclampsia at home - and it is aiming that familiar bathroom-shelf format at a condition that kills tens of thousands of mothers a year.
Preeclampsia is a pregnancy complication marked by high blood pressure and signs of organ stress, often showing up first as protein in the urine when the kidneys start to struggle. Left unmanaged, it can escalate to seizures, organ failure, and death for both mother and baby. It is the second leading cause of maternal mortality worldwide, and the deaths cluster where prenatal care is thinnest and among birthing people of color, who face the condition at greater severity. The hard part is not that preeclampsia is untreatable. It is that it is so often caught late.
01 — The originA class assignment they refused to turn in
Kalia Health did not start in a lab or a garage. It started in a classroom. The founding team met through a global-health course at Duke that paired US students with peers from Uganda's Makerere University and set them a problem: why do so many mothers in low-income countries die of preeclampsia? Denali Dahl, then a biomedical engineering doctoral student, worked the assignment with classmates including Elizabeth Ndichu, a physician from Kenya. When the course ended, most groups moved on. This one didn't.
They gathered clinical data, sketched a device, and incorporated - originally under the name Moyo Medical, "moyo" being the Swahili word for heart. In 2018 the team joined Launch Chapel Hill's accelerator and started building a lateral-flow strip they called EPED, for early preeclampsia detection. That strip is the ancestor of today's Kal-PDx. Dahl's reasoning for going the startup route rather than staying at the bench was blunt.
02 — The productWhat Kal-PDx actually does
Kal-PDx is a home-based, point-of-care urine test. The pitch is deliberately familiar: use it like a home pregnancy test. Instead of confirming a pregnancy, it looks for the early chemistry of preeclampsia - elevated protein and urinary biomarkers, including activin A and inhibin A, that show up when the condition begins to stress the kidneys. The design goals are the unglamorous ones that decide whether a test reaches anyone: non-invasive, low-cost, fast, and simple enough to read without a technician.
That word "biomarkers" is doing real work. A standard in-clinic urine dipstick can flag protein, but Kalia's bet is that reading condition-specific markers can push the warning earlier - before severe symptoms force an emergency visit. The company has been careful to say the device is still in development. It is pre-market and pre-revenue, which is the honest state of most diagnostics that are trying to clear the gap between a promising strip and a validated product.
03 — The differenceUrine at home vs blood in a clinic
The incumbent approach to preeclampsia screening is blood-based and clinic-run. Lab tests that read the sFlt-1/PlGF ratio, offered by large diagnostics companies, are accurate but require a blood draw, a clinic, and a lab. Routine prenatal care leans on blood-pressure cuffs and in-office urine dipsticks. All of it assumes the mother can reach the clinic often enough, early enough. Kalia's whole differentiation is to relax that assumption.
The incumbent
- Blood draw, clinic visit, lab turnaround
- Accurate but access-limited
- Assumes regular prenatal care
- Warning arrives when you're already there
Kalia's bet: Kal-PDx
- Urine, at home, no needle
- Low-cost, read like a pregnancy test
- Works where clinics are scarce
- Aims to move the first warning earlier
Framed that way, the competition isn't only other companies - it's the clinic itself, as a bottleneck. That framing is also why Kalia describes itself in the language of health justice rather than pure medtech. The equity angle is not marketing bolted on afterward; it is the spec. A test only helps the people preeclampsia kills most if it is cheap and simple enough to reach them.
04 — The moneyGrants, an accelerator, and the crowd
Building a diagnostic is slow and capital-hungry, and Kalia has funded the climb in pieces. It went through IndieBio / SOSV, one of the better-known early-stage biotech accelerators, which brought mentorship and investor access. It raised a convertible note, ran an equity-crowdfunding campaign on StartEngine at a roughly $8.99M valuation, and in 2025 landed a Gates Foundation Grand Challenges grant to fund a cohort study on the very urinary biomarkers behind Kal-PDx. Along the way it collected a stack of recognition awards.
Bars indicate sequence of funding and recognition milestones, not dollar amounts.
05 — The teamWho is building it
Kalia stays small - roughly five people - clustered around a core of biomedical engineering and global-health training. Denali Dahl leads as CEO. Happy Ghosh, who met Dahl during a global-health masters at Duke, runs product as Chief Product Officer. Elizabeth Ndichu, the physician from the founding class, anchors the clinical side. Around them sit advisors in diagnostic development, regulatory strategy, and obstetrics - the specific expertise a home diagnostic needs to survive the long walk to market.
The company's edge is less a single patent than a combination: engineers who can build a strip, clinicians who know how preeclampsia actually presents, and a mission specific enough to make hard product tradeoffs. In a field where plenty of maternal-health startups chase the delivery room, Kalia went upstream to the screening step - the moment where catching the condition early changes the outcome.
06 — The marketWhere a home strip fits
Kalia's business model is a B2C and direct-to-consumer medical device: a low-cost home test sold to birthing people, with a natural extension into clinics and global maternal-health programs in low-resource settings. That places it at an interesting seam of the market - part consumer health, part hardware, part global-health tooling. The addressable need is not in question; the open questions are the ones every diagnostic faces, about validation, regulatory clearance, and manufacturing at a price that keeps the equity promise real.
What a founder can take from Kalia's playbook is the move itself: take a format people already trust - the home test - and point it at a problem the medical system keeps catching too late. It only works under specific conditions. The biomarkers have to hold up in a real cohort, the manufacturing has to hit the price, and regulators have to agree. Kalia is still inside that gap. But the direction of travel - from the hospital lab toward the bathroom shelf - is a clear and copyable idea.